JAK2 and acquired polycythemia vera: Finally, we determined that the growth of EEC from circulating progenitors in PV patients (n = 5) could be inhibited at very low nanomolar concentrations of RAD001 (IC50 = 15.0±10.0 nM), PP242 (IC50 = 1.0±0.7 nM), AZD1480 (IC50 = 19.0±2.0 nM) and Ruxolitinib (IC50 = 1.8±1.0 nM), indicating a high sensitivity of these progenitors, that are considered as being mostly JAK2V617 mutated [10], [49], to both mTOR and JAK2 inhibitors.